Serum catalase to predict graft-versus-host disease after allogeneic stem cell transplantation

Kircher, B; Schumacher, P; Clausen, J; Auberger, J; Nachbaur, D BONE MARROW TRANSPL. 2009; 43: S118-S118.

A low or high body mass index is not predictive for outcome following allogeneic haematopoietic stem cell transplantation

Auberger, J; Clausen, J; Kircher, B; Gastl, G; Nachbaur, D BONE MARROW TRANSPL. 2009; 43: S373-S374.

REVERSAL OF ACUTE RENAL IMPAIRMENT BY BORTEZOMIB-DOXORUBICIN-DEXAMETHASONE IN MULTIPLE MYELOMA. RESULTS FROM AN PHASE II STUDY

Ludwig, H; Adam, Z; Greil, R; Tothova, E; Keil, F; Zojer, N; Thaler, J; Gisslinger, H; Egyed, M; Lang, A HAEMATOL-HEMATOL J. 2009; 94: 154-154.

The number needed to treat (NNT) as a measure of drug efficacy: the case of zoledronic acid for early hormone-responsive breast cancer in the ABCSG-12 trial

Gnant, M; Mlineritsch, B; Schippinger, W; Luschin-Ebengreuth, G; Steger, G; Bjelic-Radisic, V; Jakesz, R; Kubista, E; Marth, C; Greil, R CANCER RES. 2009; 69(2): 191S-191S.

Pharmacogenetic (CYP2D6) and gene expression profiles (HOXB13/IL17BR and molecular grade index) for prediction of adjuvant endocrine therapy benefit in the ABCSG 8 trial.

Goetz, M; Ames, M; Gnant, M; Filpits, M; Jakesz, R; Greil, R; Marth, C; Samonigg, H; Suman, V; Safgren, S; Kuffel, M; Weinshilboum, R; Erlander, M; Ma, XJ; Ingle, J CANCER RES. 2009; 69(2): 77S-77S.

Bevacizumab (Bev) combined with either capecitabine (X) or weekly paclitaxel (Pac) as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer (LR/MBC): the CECOG phase III TURANDOT trial

Lang, I; Inbar, M; Steger, G; Greil, R; Zvirbule, Z; Beslija, S; Kahan, Z; Taskova, V; Kaufmann, B; Zielinski, CC EJC SUPPL. 2009; 7(2): 277-278.

NUMBER NEEDED TO TREAT (NNT) AS A MEASURE OF ZOLEDRONIC ACID (ZOL) EFFICACY IN PATIENTS WITH HORMONE-RESPONSIVE EARLY BREAST CANCER (BC) IN THE AUSTRIAN BREAST AND COLORECTAL CANCER STUDY GROUP (ABCSG)-12 TRIAL

Gnant, M; Mlineritsch, B; Schippinger, W; Luschin-Ebengreuth, G; Steger, GG; Bjelic-Radisic, V; Jakesz, R; Kubista, E; Marth, C; Greil, R ANN ONCOL. 2009; 20: 30-30.

A randomized phase III study comparing epirubicin, docetaxel, and capecitabine (EDC) to epirubicin and docetaxel (ED) as neoadjuvant treatment for early breast cancer – first results of the Austrian Breast and Colorectal Cancer Study Group-Trial 24 (ABCSG-24)

Steger, GG; Greil, R; Jakesz, R; Lang, A; Mlineritsch, B; Melbinger-Zeinitzer, E; Martin, C; Samonigg, H; Kubista, E; Gnant, M EJC SUPPL. 2009; 7(3): 3-3.

Final Results of ABCSG-24, a Randomized Phase III Study Comparing Epirubicin, Docetaxel, and Capecitabine (EDC) to Epirubicin and Docetaxel (ED) as Neoadjuvant Treatment for Early Breast Cancer and Comparing ED/EDC plus Trastuzumab (T) to ED/EDC as Neoadjuvant Treatment for Early HER-2 Positive Breast Cancer

Steger, GG; Greil, R; Jakesz, R; Lang, A; Mlineritsch, B; Melbinger-Zeinitzer, E; Marth, C; Samonigg, H; Kubista, E; Gnant, M CANCER RES. 2009; 69(24): 564S-564S.

Number needed to treat (NNT) as a drug efficacy measure: Zoledronic acid (ZOL) for early hormone-responsive breast cancer in the ABCSG-12 trial

Gnant, M; Mlineritsch, B; Schippinger, W; Luschin-Ebengreuth, G; Steger, G; Bjelic-Radisic, V; Jakesz, R; Kubista, E; Marth, C; Greil, R BREAST. 2009; 18: S59-S59.